ERIS LIFESCIENCES LTD Q1 FY27 Results Analysis: PAT Surges 20.7%, Margin Compresses 2 ppt

ERIS Lifesciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 873.25 Cr (+12.97% YoY) and PAT growth of +20.68% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Eris delivered strong revenue growth of 13% YoY and PAT growth of 20.7%, but EBITDA margin compressed 2 ppt due to a material cost spike from product mix shift. Deleveraging continued with debt-equity improving to 0.64x, but the margin miss against the full-year guidance of 36% is a concern, though management had guided H1 weakness. The capex cycle for new facilities remains heavy.

Key Investment Insights

Key Positives

• Revenue grew 13.0% YoY to Rs.873.25 Cr, the strongest quarterly print in several quarters.
• PAT attributable to owners grew 20.7% YoY to Rs.142.39 Cr, outpacing EBITDA growth.
• Debt-equity ratio improved to 0.64 from 0.74 a year ago, confirming deleveraging.
• Interest service coverage ratio improved to 4.86× from 4.29×.
• Net worth grew 16% YoY to Rs.3,944 Cr.

Risk Factors

• EBITDA margin compressed 2.0 ppt YoY to 33.88%, driven by a 3.5 ppt increase in material cost as a share of revenue.
• Total material cost rose 29.6% YoY against revenue growth of 13.0%, indicating product mix shift to lower-margin products.
• Current ratio weakened to 0.60 from 0.93, reflecting working capital build-up.
• The 33.88% EBITDA margin is below the full-year guidance of 36%, though management guided H1 lower than H2.